16 / 54
Overall, the findings clarify that the benefit of pembrolizumab over
chemotherapy …
is already a current standard of care based on the
KEYNOTE-024 trial,
which previously demonstrated the superior
efficacy of pembrolizumab over chemotherapy in patients with
tumor PD-L1 expression > 50%